Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity

• Status: Unknown status
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Background: The most common pharmacologic test for diagnosis of primary aldosteronism (PA) is administration of captopril to examine whether abnormal aldosterone to plasma rennin activity (PRA)(ARR) persists, although active rennin concentration (ARC) in contrast to PRA may offers advantages with regard to processing and standardization.

Objective: To assess whether post captopril ARC offer any additional advantage in screening primary aldosteronism (PA) than PRA and establish thresholds for the diagnosis using ARC.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Collaborator: Novartis
• Treatments: Captopril

Criteria

Inclusion Criteria:

1. age at onset younger than 35 years,

2. hypertension that is difficult to control after initiating therapy,

3. clinical occurrence of a hypertensive crisis,

4. the presence of hypokaliemia or metabolic alkalosis, or a random aldosterone-renin ration (ARR) >30, and

5. evidence of adrenal incidentaloma and hypertension or hypokalemia.

Exclusion Criteria:

1. chronic kidney disease with elevated estimated glomerular filtration rate (< 60, mL/min/1.73 m2)

2. liver disease with elevated GPT (> 35)

3. heart failure

4. classified as more than NYHA II,

5. hyperthyroidism

6. malignancy with metastasis